VK2735 is Viking's experimental dual GLP-1 and GIP agonist, in development as both a pill and an injection. The late-stage program now moves the oral version forward.
Recap by typeshit. Full story at RTTNews.
U of T researchers built the AI tool with the aim of speeding up how new peptide drugs are found. The university's announcement has the details.
Fractyl plans to file a De Novo request with the FDA in late Q4, yet its shares closed about 63% lower that day over a class action and doubts about 12-month results.
Health records from 131 million adults linked GLP-1s to fewer dialysis or transplant cases. The researchers stress the study is observational and can't prove cause.
Centre Daily Times looks at how peptides taken by mouth can get past the gut intact and reach specific spots in the body, a key hurdle for pill versions of these drugs.
In a small 39-person, four month trial, both support groups regained about 3.6% of weight versus 10.75% for usual care, per Obesity Science & Practice.
RTÉ reports Lilly's new pricing offer would cost Ireland about €2 to €3 billion a year if offered publicly. A Wegovy cost assessment is due soon.
Loading…